Stock Events

Stock Events

Karyopharm Therapeutics 

$1.7900
66
+$0.02+1.13% 20:00 Today
+$0.00+0%21:14After hours

Statistics

Day High
1.84
Day Low
1.755
52W High
10.99
52W Low
1.72
Volume
576,942
Avg. Volume
1,345,790
Mkt Cap
40.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-5.71
-4.12
-2.53
-0.95
Expected EPS
-0.946
Actual EPS
N/A

Financials

-134.21%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
146.07MRevenue
-196.04MNet Income

Analyst Ratings

13.25Average Price Target
The highest estimate is 28.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KPTI. It's not an investment recommendation.
Apple
14
AAPL
Microsoft
14
MSFT
Amazon
13
AMZN
NVIDIA
11
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the oncology space with a broad portfolio of cancer treatments, overlapping with Karyopharm's focus on cancer therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences has a strong presence in the oncology and hematology market, directly competing with Karyopharm's cancer drug offerings.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a diverse range of cancer drugs that compete with Karyopharm's therapies in multiple myeloma and other cancers.
Merck
MRK
Mkt Cap366B
Merck & Co. is a leading pharmaceutical company with a strong lineup of cancer drugs that compete with Karyopharm's products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad oncology portfolio, including treatments for conditions that Karyopharm's drugs target.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in the oncology market with a focus on cancer treatments, including therapies that could be in direct competition with Karyopharm's products.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a significant presence in the oncology sector, with drugs that compete against Karyopharm's offerings in cancer treatment.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of cancer treatments, including therapies that directly compete with Karyopharm's products.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, has a portfolio of cancer drugs that compete with Karyopharm's therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, though more focused on biotechnology, has been expanding its oncology portfolio, potentially competing with Karyopharm's cancer treatments.

About

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Show more...
CEO
Richard A. Paulson
Employees
228
Country
United States
ISIN
US48576U2050
WKN
000A40YLC

Listings

STU
DE
25K0.STU
MU
DE
25K0.MU
BOATS
BOATS
KPTI.BOATS
XNAS
US
KPTI

0 Comments

Share your thoughts

FAQ

What is Karyopharm Therapeutics stock price today?▼
The current price of KPTI is $1.79 USD — it has increased by +1.13% in the past 24 hours. Watch Karyopharm Therapeutics stock price performance more closely on the chart.
What is Karyopharm Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Karyopharm Therapeutics stocks are traded under the ticker KPTI.
Is Karyopharm Therapeutics stock price growing?▼
KPTI stock has fallen by -4.28% compared to the previous week, the month change is a -8.67% fall, over the last year Karyopharm Therapeutics has showed a -73.42% decrease.
What is Karyopharm Therapeutics market cap?▼
Today Karyopharm Therapeutics has the market capitalization of 40.6M
When is the next Karyopharm Therapeutics earnings date?▼
Karyopharm Therapeutics is going to release the next earnings report on October 29, 2026.
What were Karyopharm Therapeutics earnings last quarter?▼
KPTI earnings for the last quarter are -2.32 USD per share, whereas the estimation was -1.37 USD resulting in a -69.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Karyopharm Therapeutics revenue for the last year?▼
Karyopharm Therapeutics revenue for the last year amounts to 146.07M USD.
What is Karyopharm Therapeutics net income for the last year?▼
KPTI net income for the last year is -196.04M USD.
How many employees does Karyopharm Therapeutics have?▼
As of September 04, 2026, the company has 228 employees.
In which sector is Karyopharm Therapeutics located?▼
Karyopharm Therapeutics operates in the Health & Wellness sector.
When did Karyopharm Therapeutics complete a stock split?▼
The last stock split for Karyopharm Therapeutics was on February 26, 2025 with a ratio of 1:15.
Where is Karyopharm Therapeutics headquartered?▼
Karyopharm Therapeutics is headquartered in NEWTON, United States.